CYP3A4-mediated ester cleavage as the major metabolic pathway of the oral taxane 3′-tert-butyl-3′-N-tert-butyloxycarbonyl-4-deacetyl-3′- dephenyl-3′-N-debenzoyl-4-0-methoxycarbonyl-paclitaxel (BMS-275183)

Drug Metabolism and Disposition

Volumn 37, Issue 4, 2009, Pages 710-718

  Zhang, Donglu ^a   Van Ly, T ^a   Lago, Michael ^a   Tian, Yuan ^a   Gan, Jinping ^a   Humphreys, W Griffith ^a   Çömezoǧiu, S Nilgün ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3' TERT BUTYL 3' N TERT BUTYLOXYCARBONYL 4 DEACETYL 3' N DEBENZOYL 3' DEPHENYL 4 O METHOXYCARBONYLPACLITAXEL; BACCATIN III; BENZYLNIRVANOL; COMPLEMENTARY DNA; CYTOCHROME P450 1A2; CYTOCHROME P450 2A6; CYTOCHROME P450 2B6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; CYTOCHROME P450 3A4; DIETHYLDITHIOCARBAMIC ACID; FURAFYLLINE; HYDANTOIN DERIVATIVE; KETOCONAZOLE; ORPHENADRINE; PACLITAXEL; QUERCETIN; QUINIDINE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; SULFAPHENAZOLE; TRANYLCYPROMINE; TROLEANDOMYCIN; UNCLASSIFIED DRUG;

ARTICLE; CHEMICAL BOND; CYCLIZATION; DRUG HYDROLYSIS; DRUG HYDROXYLATION; DRUG INHIBITION; DRUG METABOLISM; DRUG OXIDATION; HUMAN; HUMAN CELL; INCUBATION TIME; LIVER CYTOSOL; LIVER MICROSOME METABOLISM; METABOLITE; MICHAELIS MENTEN KINETICS; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADMINISTRATION, ORAL; ANTINEOPLASTIC AGENTS; BIOTRANSFORMATION; BRIDGED COMPOUNDS; CATALYSIS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 CYP3A; ESTERS; HUMANS; HYDROLYSIS; MICROSOMES, LIVER; TANDEM MASS SPECTROMETRY;

EID: 63849298202     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.108.024398     Document Type: Article

References (21)

1. Anderson CD, Wang J, Kumar GN, McMillan JM, Walle UK, and Walle T (1995) Dexameth- asone induction of taxol metabolism in the rat. Drug Metab Dispos 23:1286-1290.
2. Bjornsson TD, Callaghan JT, Einolf HJ, Fischer V, Gan L, Grimm S, Kao J, King SP, Miwa G, Ni L, et al. (2003) The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. Drug Metab Dispos 31:815-832.
3. Bröker LE, Veltkamp SA, Heath EI, Kuenen BC, Gall H, Astier L, Parker S, Kayitalire L, Lorusso PM, Schellens JH, et al. (2007) A phase I safety and pharmacologic study of a twice weekly dosing regimen of the oral taxane BMS-275183. Clin Cancer Res 13:3906-3912.
4. 14C]BMS275183 in bile-duct cannulated (BDC) rats. Drug Metab Rev 34 (Suppl 1):65.
5. Cresteil T, Monsarrat B, Dubois J, Sonnier M, Alvinerie P, and Gueritte F (2002) Regioselective metabolism of taxoids by human CYP3A4 and 2C8: structure-activity relationship. Drug Metab Dispos 30:438-445.
6. Frapolli R, Marangon E, Zaffaroni M, Colombo T, Falcioni C, Bagnati R, Simone M, D'Incalci M, Manzotti C, Fontana G, et al. (2006) Pharmacokinetics and metabolism in mice of IDN 5390 (13-(N-Boc-3-i-butylisoserinoyl)-C-7, 8-seco-10-deacetylbaccatin III), a new oral c- secotaxane derivative with antiangiogenic property effective on paclitaxel-resistant tumors. Drug Metab Dispos 34:2028-2035.
7. Goel S, Cohen M, Comezoglu SN, Perrin L, André F, Jayabalan D, Iacono L, Comprelli A, Ly VT, Zhang D, et al. (2008) The effect of ketoconazole on the pharmacokinetics and pharma- codynamics of ixabepilone, a first class epothilone B analog, in late phase clinical development. Clin Cancer Res 14:2701-2709.
8. Guengerich FP (1987) Oxidative cleavage of carboxylic esters by cytochrome P-450. J Biol Chem 262:8459-8462.
9. Gut I, Ojima I, Vaclavikova R, Simek P, Horsky S, Linhart I, Soucek P, Kondrova E, Kuznetsova LV, and Chen J (2006) Metabolism of new-generation taxanes in human, pig, minipig and rat liver microsomes. Xenobiotica 36:772-792.
10. 14C]BMS275183 in mouse, rat, dog, monkey and human liver microsomes. Drug Metab Rev 34 (Suppl 1):65.
11. 14C]BMS-275183, in rats and dogs. Drug Metab Dispos doi:10.1124/dmd.108.025809.
12. Marre F, Sanderink GJ, de Sousa G, Gaillard C, Martinet M, and Rahmani R (1996) Hepatic biotransformation of docetaxel (taxotere) in vitro: involvement of the CYP3A subfamily in humans. Cancer Res 56:1296-1302.
13. Rodrigues AD (1999) Integrated cytochrome P450 reaction phenotyping: attempting to bridge the gap between cDNA-expressed cytochromes P450 and native human liver microsomes. Biochem Pharmacol 57:465-480.
14. Rose WC, Long BH, Fairchild CR, Lee FYF, and Kadow JF (2001) Preclinical pharmacology of BMS-275183, an orally active taxane. Clin Cancer Res 2016:2016-2021.
15. Saville MW, Lietzau J, Pluda JM, Feuerstein I, Odom J, Wilson WH, Humphrey RW, Feigal E, Steinberg SM, and Broder S (1995) Treatment of HIV-associated Kaposi's sarcoma with paclitaxel. Lancet 346:26-28.
16. Taniguchi R, Kumai T, Matsumoto N, Watanabe M, Kamio K, Suzuki S, and Kobayashi S (2005) Utilization of human liver microsomes to explain individual differences in paclitaxel metabolism by CYP2C8 and CYP3A4. J Pharmacol Sci 97:83-90.
17. Wall ME and Wani MC (1995) Camptothecin and Taxol: discovery to clinic-thirteenth Bruce F. Cain Memorial Award Lecture. Cancer Res 55:753-760.
18. Wang L, Christopher LJ, Cui D, Li W, Iyer R, Humphreys WG, and Zhang D (2008) Identification of the human enzymes involved in the oxidative metabolism of dasatinib: an effective approach for determining metabolite formation kinetics. Drug Metab Dispos 36:1828-1839.
19. Zhang D, Wang L, Chandrasena G, Ma L, Zhu M, Zhang H, Davis CD, and Humphreys WG (2007) Involvement of multiple cytochrome P450 and UDP-glucuronosyltransferase enzymes in the in vitro metabolism of muraglitazar. Drug Metab Dispos 35:139-149.
20. Zhang JW, Ge GB, Liu Y, Wang LM, Liu XB, Zhang YY, Li W, He YQ, Wang ZT, Sun J, et al. (2008) Taxane's substituents at C3′ affect its regioselective metabolism: different in vitro metabolism of cephalomannine and paclitaxel. Drug Metab Dispos 36:418-426.
21. Zhao W, Wang L, Zhu M, and Zhang D (2009) Rapid and sensitive characterization of the metabolite formation enzyme kinetics of radiolabeled drugs using stop-flow liquid radiochro- matography. Drug Metab Lett 2:41-46.